These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 5571114)
1. Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa. Wilk S; Mones R J Neurochem; 1971 Sep; 18(9):1771-3. PubMed ID: 5571114 [No Abstract] [Full Text] [Related]
2. 3 -Methoxy- 4 -hydroxyphenylethylene glycol in human cerebrospinal fluid. Gordon EK; Oliver J Clin Chim Acta; 1971 Nov; 35(1):145-50. PubMed ID: 4256760 [No Abstract] [Full Text] [Related]
3. Cerebrospinal fluid homovanillic acid and iso-homovanillic acid: a gas-liquid chromatographic method. Dziedzic SW; Gitlow SE J Neurochem; 1974 Mar; 22(3):333-5. PubMed ID: 4829959 [No Abstract] [Full Text] [Related]
4. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa. Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176 [No Abstract] [Full Text] [Related]
5. Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. Chase TN; Gordon EK; Ng LK J Neurochem; 1973 Sep; 21(3):581-7. PubMed ID: 4270247 [No Abstract] [Full Text] [Related]
6. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Weiner W; Harrison W; Klawans H Life Sci; 1969 Sep; 8(17):971-6. PubMed ID: 5808572 [No Abstract] [Full Text] [Related]
7. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF. Godwin-Austen RB J Neurol Neurosurg Psychiatry; 1971 Jun; 34(3):219-23. PubMed ID: 5571307 [TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa. Johansson B; Roos BE Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306 [No Abstract] [Full Text] [Related]
10. Correlations between a fluorimetric and mass fragmentographic method for the determination of 3-methoxy-4-hydroxyphenylacetic acid and two mass fragmentographic methods for the determination of 3-methoxy-4- hydroxyphenylethylene glycol in cerebrospinal fluid. Muskiet FA; Jeuring HJ; Korf J; Sedvall G; Westerink BH; Teelken AW; Wolthers BG J Neurochem; 1979 Jan; 32(1):191-4. PubMed ID: 759571 [No Abstract] [Full Text] [Related]
11. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa). Sharpless NS; Ericsson AD; McCann DS Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098 [No Abstract] [Full Text] [Related]
12. Parkinsonism-dementia of Guam: treatment with L-dopa. Schnur JA; Chase TN; Brody JA Neurology; 1971 Dec; 21(12):1236-42. PubMed ID: 4257247 [No Abstract] [Full Text] [Related]
13. The determination of 4-hydroxy-3-methoxyphenylethylene glycol in urine and CSF using gas chromatography. Bond PA Biochem Med; 1972 Feb; 6(1):36-45. PubMed ID: 4260101 [No Abstract] [Full Text] [Related]
14. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease. van Woert MH; Bowers MB Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981 [No Abstract] [Full Text] [Related]